SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 15, 2012
THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
(State or other jurisdiction
|(Commission File Number)
170 Harbor Way, Suite 300
South San Francisco, California 94080
(Address of principal executive offices)(Zip
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On November 15, 2012, Threshold Pharmaceuticals, Inc. issued
a press release announcing updated results from a Phase 2 study of TH-302, the company’s investigational hypoxia-targeted
drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent
maintenance therapy following induction with TH-302 in combination with doxorubicin. The press
release is attached as Exhibit 99.1 to this Form 8-K.
|Item 9.01||Financial Statements and Exhibits.
|Exhibit 99.1||Press release dated November 15, 2012.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
||THRESHOLD PHARMACEUTICALS, INC.|
||/s/ Joel A. Fernandes|
||Joel A. Fernandes|
Vice President, Finance and Controller
Date: November 15, 2012
||Press release dated November 15, 2012.|